COLUMBIA, Md.--(BUSINESS WIRE)--Ambu Inc., a rapidly growing medical device maker and pioneer of sterile, single-use endoscopes, introduced today a new single-use cystoscope. The Ambu® aScope™ 4 Cysto ...
Please provide your email address to receive an email when new articles are posted on . Cystoscopies for recurrent UTIs yield little clinical benefit for patients both with and without high-risk ...
A simple urine test can more than halve the number of cystoscopies necessary to follow up high-risk bladder cancer patients, new research has found. Cystoscopies involve inserting a flexible probe ...
Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
A new urine test could spare bladder cancer survivors from a painful follow-up procedure needed to ensure their cancer hasn't come back, researchers report. People who've gotten surgery for high-risk ...
Ambu Inc., a rapidly growing medical device maker and pioneer of sterile, single-use endoscopes, announced today that it has received Health Canada clearance for the aScopeTM 4 Cysto, the company’s ...
Researchers led by the University of Ulsan College of Medicine, Korea, have checked the performance of a noninvasive urinary DNA methylation test for bladder cancer diagnosis. Injected micronized ...
We used four deep learning models (ConvNeXt, PlexusNet, MobileNet, and SwinTransformer) covering a variety of model complexity and efficacy. We trained these models on a previously published ...
Researchers led by the University of Ulsan College of Medicine, Korea, have checked the performance of a noninvasive urinary DNA methylation test for bladder cancer diagnosis. Injected micronized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results